Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neurocrine Bioscienc 6027 Edgewood Bend Court San Diego CA 92130 USA

www.neurocrine.com Employees: 1,800 P: 858-617-7600

Sector:

Medical

Description:

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Key Statistics

Overview:

Market Capitalization, $K 15,235,078
Enterprise Value, $K 15,002,078
Shares Outstanding, K 99,706
Annual Sales, $ 2,355 M
Annual Net Income, $ 341,300 K
Last Quarter Sales, $ 794,900 K
Last Quarter Net Income, $ 209,500 K
EBIT, $ 550,200 K
EBITDA, $ 551,100 K
60-Month Beta 0.27
% of Insider Shareholders 4.80%
% of Institutional Shareholders 92.59%
Float, K 94,920
% Float 95.20%
Short Volume Ratio 0.53

Growth:

1-Year Return 20.51%
3-Year Return 30.39%
5-Year Return 50.65%
5-Year Revenue Growth 198.86%
5-Year Earnings Growth 743.59%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.04 on 10/28/25
Next Earnings Date 02/05/26
Earnings Per Share ttm 4.18
EPS Growth vs. Prev Qtr 92.45%
EPS Growth vs. Prev Year 64.52%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payable Date 12/31/69
Dividend Payout Ratio 0.00%

NBIX Ratios

Ratio
Price/Earnings ttm 37.02
Price/Earnings forward 29.16
Price/Earnings to Growth 1.02
Return-on-Equity % 15.82%
Return-on-Assets % 11.00%
Profit Margin % 14.49%
Debt/Equity 0.00
Price/Sales 6.55
Price/Cash Flow 45.79
Price/Book 5.14
Book Value/Share 30.12
Interest Coverage -1.48
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar